Research
Hormonal
Semax enhances neuroplasticity and cognitive function in aging by upregulating BDNF and modulating neurotransmitter systems, showing benefits in stroke recovery and cognitive decline.
Semax is a peptide that may improve brain health by increasing BDNF, a key factor in neuroplasticity. Russian studies suggest it can help stroke recovery and cognitive function, but it is not FDA-approved for these uses, and independent Western validation is lacking.
LimitedSupportsLOW confidence
Semax’s primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF)... Administration of Semax produces 1.4-fold increases in hippocampal BDNF protein levels... Clinical evidence from Russian studies demonstrates Semax’s utility in age-related cognitive conditions. Trials in elderly stroke patients showed improved neurological recovery.
Why this rating
Evidence is from Russian clinical trials and animal studies; lacks independent Western validation.
Source
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Volodymyr Mavrych et al. · Frontiers in Aging · 2026
DOI 10.3389/fragi.2026.1790247
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.Strong
- CJC-1295 and Ipamorelin restore youthful growth hormone secretion patterns by preserving physiological pulsatility, avoiding the adverse effects of continuous exogenous GH administration.Moderate
- Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →